Satyajit Rajapurkar

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 333 citations · Full text

Cancer Research, Mtap Loss, Medicine +10

Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo

Raymond E. Soccio, Eric R. Chen, Satyajit Rajapurkar et al. · Cell · 2015 · 122 citations · Full text

Genetic Determinant, Medicine, Genetics +6

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes

Kimberly N. Smitheman, Tesa Severson, Satyajit Rajapurkar et al. · Haematologica · 2018 · 63 citations · Full text

Targeting PPARγ in the epigenome rescues genetic metabolic defects in mice

Raymond E. Soccio, Zhenghui Li, Eric R. Chen et al. · Journal of Clinical Investigation · 2017 · 54 citations · Full text

Genetics, Brown Fat, Caloric Restriction +24

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Anastasia Wyce, Jeanne J. Matteo, Shawn W. Foley et al. · Oncogenesis · 2018 · 33 citations · Full text